Compare MDWD & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDWD | EDAP |
|---|---|---|
| Founded | 2000 | 1979 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.3M | 163.4M |
| IPO Year | 2013 | 1998 |
| Metric | MDWD | EDAP |
|---|---|---|
| Price | $16.67 | $3.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $36.00 | $2.00 |
| AVG Volume (30 Days) | ★ 83.2K | 40.3K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,527,000.00 |
| Revenue This Year | $48.88 | N/A |
| Revenue Next Year | $35.08 | $10.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $14.77 | $1.21 |
| 52 Week High | $22.51 | $5.05 |
| Indicator | MDWD | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 37.87 |
| Support Level | N/A | $3.32 |
| Resistance Level | $18.71 | $4.32 |
| Average True Range (ATR) | 0.80 | 0.33 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 63.08 | 32.41 |
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.